ES2118677T3 - Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. - Google Patents

Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.

Info

Publication number
ES2118677T3
ES2118677T3 ES96921197T ES96921197T ES2118677T3 ES 2118677 T3 ES2118677 T3 ES 2118677T3 ES 96921197 T ES96921197 T ES 96921197T ES 96921197 T ES96921197 T ES 96921197T ES 2118677 T3 ES2118677 T3 ES 2118677T3
Authority
ES
Spain
Prior art keywords
active agent
composition
glass
pct
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96921197T
Other languages
English (en)
Other versions
ES2118677T1 (es
Inventor
Ake Lindahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioglan AB
Original Assignee
Bioglan AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan AB filed Critical Bioglan AB
Publication of ES2118677T1 publication Critical patent/ES2118677T1/es
Application granted granted Critical
Publication of ES2118677T3 publication Critical patent/ES2118677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processing Of Solid Wastes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

FORMULACION BIOLOGICAMENTE ACTIVA COMPUESTA DE UNA SOLUCION DE UN AGENTE ACTIVO DISUELTO EN UN VEHICULO VITRIFICANTE, QUE CONTIENE UNA SUSTANCIA VITRIFICANTE (A) CON UN PLASTIFICANTE (B) CUYA CANTIDAD DEBE SELECCIONARSE PREFERIBLEMENTE DE FORMA QUE LA FORMULACION ADQUIERA UNA CONSISTENCIA NO SOLIDA. LA FORMULACION PUEDE PREPARARSE DISOLVIENDO EL AGENTE ACTIVO EN UNA MEZCLA FUNDIDA DE LA SUSTANCIA VITRIFICANTE Y EL PLASTIFICANTE A UNA TEMPERATURA INFERIOR A LA TEMPERATURA DE DESINTEGRACION DEL AGENTE ACTIVO REFERIDO. UTILIZACION DEL VEHICULO VITRIFICANTE PARA LA DISOLUCION DE UN AGENTE BIOLOGICAMENTE ACTIVO.
ES96921197T 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. Expired - Lifetime ES2118677T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Publications (2)

Publication Number Publication Date
ES2118677T1 ES2118677T1 (es) 1998-10-01
ES2118677T3 true ES2118677T3 (es) 2001-10-16

Family

ID=20398685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96921197T Expired - Lifetime ES2118677T3 (es) 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.

Country Status (14)

Country Link
US (1) US6083518A (es)
EP (1) EP0833611B1 (es)
JP (1) JP4020331B2 (es)
AT (1) ATE204466T1 (es)
AU (1) AU695622B2 (es)
CA (1) CA2225286C (es)
DE (2) DE833611T1 (es)
DK (1) DK0833611T3 (es)
ES (1) ES2118677T3 (es)
NZ (1) NZ311208A (es)
PT (1) PT833611E (es)
SE (1) SE9502244D0 (es)
WO (1) WO1997000670A1 (es)
ZA (1) ZA965237B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4512700B2 (ja) * 2003-06-02 2010-07-28 トーアエイヨー株式会社 アシクロビル含有水溶液製剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
WO2005113147A2 (en) 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
GB2432528B (en) * 2005-11-29 2011-04-06 Ian Ripley Anti-viral compositions comprising flavanone glycosides and fruit acids
JP5184342B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
PL2005958T3 (pl) * 2006-03-08 2013-11-29 Nihon Nohyaku Co Ltd Kompozycja farmaceutyczna do stosowania zewnętrznego
JP5184341B2 (ja) * 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
MX2008015599A (es) 2006-06-14 2009-03-06 Reddys Lab Ltd Dr Composiciones topicas.
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
KR100721126B1 (ko) 2006-12-28 2007-05-23 (주)바이오앤에이치엔티 모기 기피제 조성물
WO2009031643A1 (ja) 2007-09-05 2009-03-12 Pola Pharma Inc. 抗真菌組成物
US20100204293A1 (en) * 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
HUE030028T2 (en) * 2007-09-05 2017-04-28 Pola Pharma Inc Antifungal drug
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5421901B2 (ja) 2008-03-31 2014-02-19 国立大学法人広島大学 エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
EP2321303B1 (en) 2008-08-27 2019-11-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE032022T2 (en) 2009-01-09 2017-08-28 Egyt Gyogyszervegyeszeti Gyar Medicinal product with improved effect
EP2395839B1 (en) 2009-02-13 2014-05-07 Topica Pharmaceuticals, Inc Anti-fungal formulation
EP2416757A2 (en) 2009-04-09 2012-02-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5688406B2 (ja) 2009-04-09 2015-03-25 株式会社ポーラファルマ 抗真菌医薬組成物
EP2470178B1 (en) 2009-08-25 2018-10-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
WO2019094434A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
JP2021502388A (ja) 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
GB2591681A (en) 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US12251405B2 (en) 2018-10-03 2025-03-18 Myos Corp. Spray dried follistatin product
NL2021864B1 (en) * 2018-10-24 2020-05-13 Seranovo B V Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
WO2020085904A2 (en) 2018-10-24 2020-04-30 SeraNovo B.V. Deep eutectic solvent platform for oral pharmaceutical formulations
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
SG11202109899VA (en) 2019-03-15 2021-10-28 Unicycive Therapeutics Inc Nicorandil derivatives
CN116113406B (zh) 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
EP4604978A2 (en) 2022-10-19 2025-08-27 Myos Corp. Myogenic compounds
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
USRE33221E (en) 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0319988A1 (en) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha External dermatological composition
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
WO1993011749A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company A process for the preparation of a solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
ZA965237B (en) 1997-01-09
ES2118677T1 (es) 1998-10-01
DE833611T1 (de) 1999-01-07
SE9502244D0 (sv) 1995-06-20
US6083518A (en) 2000-07-04
JP4020331B2 (ja) 2007-12-12
JPH11508250A (ja) 1999-07-21
ATE204466T1 (de) 2001-09-15
CA2225286A1 (en) 1997-01-09
WO1997000670A1 (en) 1997-01-09
DK0833611T3 (da) 2001-10-08
AU6247396A (en) 1997-01-22
HK1008774A1 (en) 1999-05-21
EP0833611B1 (en) 2001-08-22
CA2225286C (en) 2003-06-10
DE69614689D1 (de) 2001-09-27
AU695622B2 (en) 1998-08-20
PT833611E (pt) 2002-01-30
NZ311208A (en) 1999-03-29
EP0833611A1 (en) 1998-04-08
DE69614689T2 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
ES2118677T3 (es) Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.
NO971965D0 (no) Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav
HU9603530D0 (en) Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR0007147A (pt) Composição de tensìdio contendo tensìdio gemini e co-anfifila, sua preparação e aplicação
CO5070580A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
ATE260649T1 (de) Pharmazeutische formulierung und dosierform bestehend aus polysacchariden zur kontrollierten wirkstoff-freisetzung im dickdarm
DK1299108T3 (da) Parasiticidt præparat samt fremgangsmåde til fremstilling af dette præparat
FI103091B1 (fi) Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
BRPI0409345A (pt) sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
PT801559E (pt) Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
BR0015538A (pt) Emprego de polissiloxanos com grupos amino quaternários como coadjuvantes de formulação, e agentes contendo-os
ES2163147T3 (es) Perfeccionamientos de agentes antimicrobianos de accion prolongada o relativos a los mismos.
BR9807365A (pt) Composição para destruir células epiteliais de pigmento retinal e células proliferativas
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem
ES2155048T3 (es) Composicion biologicamente activa.
NZ508074A (en) Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
ATE19472T1 (de) Verwendung von 5-phenyl-1,4-benzodoazepinen zur herstellung von analgetisch wirksamen pharmazeutischen zubereitungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833611

Country of ref document: ES